Bulk transcriptomics integrated 2,986 cervical samples (normal, precancerous, para-tumor, carcinoma) across 50 datasets,with expression and clinical/prognostic data (available).

Single-cell transcriptomics integrated 202 cervical samples (normal, precancerous, para-tumor, carcinoma) across 19 datasets. Re-annotation enables exploration of gene expression within cell subtypes.

Spatial transcriptomics profiled 26 in-house cervical samples (normal/cancer) across 2 datasets. Re-annotation enables spatial mapping and expression analysis of target genes.

HPV integration profiled 307 in-house cervical samples (normal, precancerous, carcinoma) across 3 datasets. Users enable explore the HPV integration frequency and location in target genes.

The pan-cancer cohort comprised 1,022 patients across 22 datasets (15 cancer types) treated with anti-PD-(L)1 or CTLA-4. Expression and clinical data enable differential gene analysis by treatment response.